October 16 – 19, 2023 | San Diego, CA
The ADC renaissance shows no sign of slowing down with the ground-breaking approval of ELAHERE for platinum-resistant ovarian cancer, Pfizer’s jaw-dropping acquisition of Seagen for $43 billion, and BMS’ $1 billion+ pact with Tubulis. There has been no better time to reunite the World ADC community and invest in progressing ADCs to front-line treatments for patients.
The highly anticipated 14th World ADC San Diego returns as the world’s largest industry-dedicated discussion and networking forum addressing and overcoming the challenges in end-to-end ADC development.
Joining 120+ industry-leading speakers and reviewing the current state of the ADC landscape, is Beacon’s expert Account Manager, Jake Morris. This is one not to be missed.
Don’t miss out on the chance to reunite with the antibody-drug conjugate community while reflecting on the exciting year that ADCs have had, and building momentum for the future of this innovative field.
